It follows second Ebola death in densely populated city of Goma, on Rwandan border
Rwanda has closed its border with the Democratic Republic of Congo, where a deadly Ebola outbreak that started a year ago has killed more than 1,803 people.
The closure came after a second death linked to the Ebola virus was confirmed in the densely populated Congolese city of Goma, which is on the porous border with Rwanda.
The World Health Organization, which declared the DRC outbreak a global health emergency last month, has recommended against travel or trade restrictions. It has also said the risk of regional spread was “very high”.
The DRC presidency’s office said it regretted what it described as a unilateral decision by the Rwandan authorities to restrict movement at the border, “which runs counter to the advice of the World Health Organization”.
Earlier on Thursday, a DRC official said a person who had had contact with the second confirmed Ebola case in Goma was at a treatment centre after showing signs of the disease.
It was not immediately clear whether the person was a family member of the man who died on Wednesday. He had spent several days at home with his family while showing symptoms.
If this suspected case is confirmed, it could be the first transmission of Ebola in this outbreak inside Goma, a city of more than 2 million people. The escalating crisis has led to a row within the DRC’s health ministry, which is co-ordinating national efforts to contain the spread of the virus.
Last week the DRC’s health minister, Oly Ilunga Kalenga, resigned in protest of the country’s handling of the Ebola outbreak. He said international agencies were pressuring his government to allow the testing of a new vaccine developed by Johnson & Johnson. The row over the vaccine trials began after Ilunga reportedly banned clinical trials of the new vaccine in DRC. Ebola vaccines are difficult to develop because they have to be tested during outbreaks.
In the previous outbreak in west Africa, one vaccine, produced by Merck, was successfully trialled in Guinea. The success of that trial meant preventative Merck vaccines could be given to citizens in the DRC and potentially contain the outbreak.
Ilunga has argued trialling vaccines in Ebola-affected regions could erode public trust in the government. Merck’s vaccine requires only a single shot, whereas Johnson & Johnson’s new vaccine has to be taken in two doses.
Officials and NGOs fear discrepancies in the vaccination schedules – with some people getting one shot and others two – could fuel rumours about the vaccines in local communities.
Ilunga also said delivering two doses would be logistically difficult in a region where there was a high rate of displacement.
Think your friends would be interested? Share this story!
